A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 86 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 64th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 21 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 451 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 112th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 308th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 451 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: placebo
Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26
The estimated mean change from baseline in HbA1c after 26 weeks of treatment.
Time frame: Week 0 to Week 26
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
The estimated mean change from baseline in FPG after 26 weeks of treatment.
Time frame: Week 0 to Week 26
Change in Mean Self-Measured Plasma Glucose (SMPG) of 7-Point Profile From Baseline to Week 26
The estimated mean change from baseline in mean SMPG of 7-point profile (7-points were before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime) after 26 weeks of treatment.
Time frame: Week 0 to Week 26
Change in Body Weight From Baseline to Week 26
The estimated mean change in body weight after 26 weeks of treatment.
Time frame: Week 0 to Week 26
Number of Subjects Achieving HbA1c Below 7.0% (American Diabetes Association [ADA] Target)
Number of subjects achieving HbA1c below 7.0% (American Diabetes Association \[ADA\] target) after 26 weeks of treatment
Time frame: At Week 26
Number of Subjects Achieving HbA1c Below or Equal to 6.5% (American Association of Clinical Endocrinologists [AACE] Target)
Number of subjects achieving HbA1c below or equal to 6.5% (American Association of Clinical Endocrinologists \[AACE\] target) after 26 weeks of treatment.
Time frame: At Week 26
Number of Adverse Events (AEs) During The Randomised Treatment Period
An AE was defined as treatment emergent if the onset date (or increase in severity) was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. The adverse events were categorised as 'serious' and 'non-serious' adverse events. Adverse events were also categorised according to the severity as 'mild', 'moderate' and 'severe' adverse events.
Time frame: Week 0 to Week 26 + 7 days follow up
Number of Minor Hypoglycaemic Episodes During The Randomised Treatment Period
A minor hypoglycaemic episode was defined as either, (a) an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) that was handled by the subject him/herself or (b) any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL).
Time frame: Week 0 to Week 26 + 7 days follow up
Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period
Severe hypoglycaemia episode was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
Time frame: Week 0 to Week 26 + 7 days follow up
The trial was conducted at 76 sites in 9 countries i.e. 3 sites in Argentina; 9 sites in Canada; 5 sites in Finland; 9 sites in Germany; 9 sites in India; 2 sites in Mexico; 7 sites in Netherlands; 3 sites in Serbia; 29 sites in United States.
| Milestone | Liraglutide | Placebo |
|---|---|---|
| Started | 226 | 225 |
| Exposed | 225 | 225 |
| Completed | 191 | 174 |
| Not completed | 35 | 51 |
| Withdrew: Adverse event | 12 | 3 |
| Withdrew: Protocol violation | 8 | 7 |
| Withdrew: Withdrawal criteria | 12 | 37 |
| Withdrew: Unclassified | 3 | 4 |
The estimated mean change from baseline in HbA1c after 26 weeks of treatment.
| percentage of glycosylated haemoglobin | Liraglutide | Placebo |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 | -1.30 ± 1.015 | -0.11 ± 1.088 |
The estimated mean change from baseline in FPG after 26 weeks of treatment.
| mmol/L | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 | -1.44 ± 2.494 | -0.16 ± 3.006 |
The estimated mean change from baseline in mean SMPG of 7-point profile (7-points were before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime) after 26 weeks of treatment.
| mmol/L | Liraglutide | Placebo |
|---|---|---|
| Change in Mean Self-Measured Plasma Glucose (SMPG) of 7-Point Profile From Baseline to Week 26 | -2.61 ± 2.248 | -1.02 ± 3.061 |
The estimated mean change in body weight after 26 weeks of treatment.
| kg | Liraglutide | Placebo |
|---|---|---|
| Change in Body Weight From Baseline to Week 26 | -3.54 ± 3.669 | -0.42 ± 3.909 |
Number of subjects achieving HbA1c below 7.0% (American Diabetes Association \[ADA\] target) after 26 weeks of treatment
| percentage of subjects | Liraglutide | Placebo |
|---|---|---|
| Number of Subjects Achieving HbA1c Below 7.0% (American Diabetes Association [ADA] Target) | 59.24 | 14.02 |
Number of subjects achieving HbA1c below or equal to 6.5% (American Association of Clinical Endocrinologists \[AACE\] target) after 26 weeks of treatment.
| percentage of subjects | Liraglutide | Placebo |
|---|---|---|
| Number of Subjects Achieving HbA1c Below or Equal to 6.5% (American Association of Clinical Endocrinologists [AACE] Target) | 42.91 | 3.60 |
An AE was defined as treatment emergent if the onset date (or increase in severity) was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. The adverse events were categorised as 'serious' and 'non-serious' adverse events. Adverse events were also categorised according to the severity as 'mild', 'moderate' and 'severe' adverse events.
| Events/1000 years of patient exposure | Liraglutide | Placebo |
|---|---|---|
| Adverse Events | 4918 | 3737 |
| Serious Adverse Events | 149 | 101 |
| Severe Adverse Events | 169 | 101 |
| Moderate Adverse Events | 1274 | 1060 |
| Mild Adverse Events | 3474 | 2575 |
A minor hypoglycaemic episode was defined as either, (a) an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) that was handled by the subject him/herself or (b) any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL).
| Events/100 years of patient exposure | Liraglutide | Placebo |
|---|---|---|
| Number of Minor Hypoglycaemic Episodes During The Randomised Treatment Period | 126 | 83 |
Severe hypoglycaemia episode was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
| Events/100 years of patient exposure | Liraglutide | Placebo |
|---|---|---|
| Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period | 0 | 0 |
Collected over Week 0 to Week 26 + 7 days follow up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide | — | 11/225 (4.9%) | 103/225 (45.8%) |
| Placebo | — | 7/225 (3.1%) | 46/225 (20.4%) |
| Event | Liraglutide | Placebo |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/225 | 2/225 |
| Acute myocardial infarctionCardiac disorders | 1/225 | 0/225 |
| IleusGastrointestinal disorders | 1/225 | 0/225 |
| Arthritis bacterialInfections and infestations | 0/225 | 1/225 |
| Cellulitis staphylococcalInfections and infestations | 1/225 | 0/225 |
| Ear infectionInfections and infestations | 1/225 | 0/225 |
| GastroenteritisInfections and infestations | 1/225 | 0/225 |
| Genital herpesInfections and infestations | 1/225 | 0/225 |
| OsteomyelitisInfections and infestations | 0/225 | 1/225 |
| PneumoniaInfections and infestations | 1/225 | 0/225 |
| Event | Liraglutide | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 50/225 | 7/225 |
| DiarrhoeaGastrointestinal disorders | 24/225 | 11/225 |
| Decreased appetiteMetabolism and nutrition disorders | 22/225 | 5/225 |
| VomitingGastrointestinal disorders | 20/225 | 2/225 |
| DyspepsiaGastrointestinal disorders | 16/225 | 2/225 |
| InfluenzaInfections and infestations | 8/225 | 16/225 |
| Lipase increasedInvestigations | 16/225 | 5/225 |
| HeadacheNervous system disorders | 8/225 | 16/225 |
| NasopharyngitisInfections and infestations | 13/225 | 14/225 |
| Back painMusculoskeletal and connective tissue disorders | 12/225 | 12/225 |
| Age, Continuous(years) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Mean | 59.3 ± 9.2 | 57.5 ± 11.1 | 58.4 ± 10.2 |
| Sex: Female, Male(Participants) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Female | 105 | 89 | 194 |
| Male | 120 | 136 | 256 |
| Body Weight(kg) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Mean | 90.23 ± 19.98 | 91.85 ± 21.33 | 91.04 ± 20.66 |
| Fasting Plasma Glucose (FPG)(mmol/L) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Mean | 8.32 ± 2.89 | 8.21 ± 2.90 | 8.27 ± 2.89 |
| Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Mean | 8.22 ± 0.81 | 8.28 ± 0.90 | 8.25 ± 0.86 |
The record gives a start of Sep 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide